IC
XFOR icon

Ikarian Capital’s X4 Pharmaceuticals XFOR Stock Holding History

Ikarian Capital’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,638
Closed -$677K – 173
2023
Q2 		$677K Hold
11,638
– – 0.11% 93
2023
Q1 		$304K Hold
11,638
– – 0.07% 101
2022
Q4 		$347K Sell
11,638
-7,316
-39% -$347K 0.08% 66
2022
Q3 		$973K Sell
18,954
-37,038
-66% -$1.28M 0.19% 69
2022
Q2 		$1.62M Buy
55,992
+10,258
+22% +$390K 0.3% 65
2022
Q1 		$2.4M Sell
45,734
-29,749
-39% -$1.71M 0.32% 59
2021
Q4 		$5.19M Sell
75,483
-9,181
-11% -$1.16M 0.77% 33
2021
Q3 		$13.4M Sell
84,664
-5,979
-7% -$984K 0.95% 24
2021
Q2 		$17.7M Buy
90,643
+3,477
+4% +$874K 1.43% 14
2021
Q1 		$22.5M Buy
87,166
+59,619
+216% +$15.7M 0.76% 31
2020
Q4 		$5.31M Buy
27,547
+3,391
+14% +$666K 0.23% 90
2020
Q3 		$4.91M Buy
24,156
+23,989
+14,365% +$5.75M 0.36% 69
2020
Q2 		$47K Buy
+167
New +$45.7K ﹤0.01% 161
2020
Q1 		– Sell
-333
Closed -$107K – 177
2019
Q4 		$107K Buy
+333
New +$119K 0.02% 106

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital's XFOR Position: Q3 2023 in Review

Ikarian Capital sold out of X4 Pharmaceuticals (XFOR) in Q3 2023, closing a stake of 11,638 shares — an estimated $677K sold.

Ikarian Capital first reported a position in XFOR in Q4 2019 and held it in 14 quarters. The position peaked at $22.5M in Q1 2021. 91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

  • Ikarian Capital reported no remaining X4 Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 11,638 X4 Pharmaceuticals shares in Q3 2023, an estimated $677K.
  • Ikarian Capital first reported a position in X4 Pharmaceuticals in Q4 2019 and held it in 14 quarters.
  • Ikarian Capital's X4 Pharmaceuticals position peaked at $22.5M in Q1 2021.
  • 91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.